文献速递临床血液与体液分子诊断质量管理与危急值

甲状腺细针穿刺诊断观察者间一致性:判读者经验与分子诊断的影响

Diagnostic interobserver agreement for thyroid fine-needle aspirates: Effects of reviewer experience and molecular diagnostics.
PubMed 文献 · Am J Clin Pathol · 2024-01-01

该研究评估携带BRAF V600E的甲状腺AUS(意义不明的异型性)细针穿刺的观察者间一致性,并与非BRAF V600E病例对比,关注细胞病理经验。七名判读者(含3名受训者和3名委员会认证细胞病理学家)评估24例FNA,其中5例为BRAF V600E阳性AUS。经验更丰富的细胞病理学家间一致性更高,BRAF V600E病例的模式诊断在5例中有4例为AUS。建议对此类病例进行BRAF V600全测序。

要点

  • 携带BRAF V600E的AUS甲状腺FNA不常见但重复性较好
  • 经验更丰富的细胞病理学家观察者间一致性更高
  • 建议对AUS甲状腺FNA进行BRAF V600全测序

核心结论

  • 携带BRAF V600E的甲状腺AUS细针穿刺不常见但相对可重复,尤其在经验丰富的病理学家中。
  • 对此类病例建议进行BRAF V600全测序。

研究设计与样本

  • 七名判读者评估5例携带BRAF V600E的AUS甲状腺FNA,并与19例其他TBSRTC类别且携带非BRAF V600E遗传改变的FNA混合(共24例)。
  • 另独立评估4例BRAF V600E病例;判读者包括3名受训者和3名美国病理学委员会认证的细胞病理学家。

主要发现

  • BRAF V600E在260例AUS FNA中检出5例(2%)。
  • 在携带RAS样改变的11例中,有6例的模式诊断与索引诊断不同。
  • 在5例BRAF V600E FNA中,有4例的模式诊断为AUS。

关键数值与推荐

  • BRAF V600E在AUS FNA中的检出率为5/260(2%)。
  • 模式诊断与索引诊断不一致的病例为6/11(携带RAS样改变)。
  • 模式诊断为AUS的BRAF V600E病例为4/5。

临床怎么用

  • 对AUS甲状腺FNA应考虑BRAF V600全测序以识别BRAF V600E。
  • 判读经验影响观察者间一致性,经验丰富的细胞病理学家一致性更高。

局限性

  • 样本量小(共24例FNA,其中BRAF V600E AUS 5例)。
  • 判读者数量有限(7名),包括受训者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Few cytologically indeterminate thyroid fine-needle aspirations (FNAs) harbor BRAF V600E. Here, we assess interobserver agreement for The Bethesda System for Reporting Thyroid Cytopathology (TBSRTC) category III (atypia of undetermined significance [AUS]) FNAs harboring BRAF V600E and contrast their features with those harboring non-BRAF V600E alterations, with attention to cytopathology experience. METHODS: Seven reviewers evaluated 5 AUS thyroid FNAs harboring BRAF V600E. To blind reviewers, cases were intermixed with 19 FNAs falling within other TBSRTC categories and in which genetic alterations other than BRAF V600E had been identified (24 FNAs total). Interobserver agreement against both "index" and most popular ("mode") diagnoses was calculated. Four additional BRAF V600E cases were independently reviewed. RESULTS: Reviewers included 3 trainees and 3 American Board of Pathology (board)-certified cytopathologists. Board-certified cytopathologists, whose experience ranged from 2 to more than 15 subspecialty practice years, had known AUS rates. BRAF V600E was identified in 5 of 260 (2%) AUS FNAs. Interobserver agreement was higher among cytopathologists with more experience. Mode diagnosis differed from index diagnosis in 6 of 11 cases harboring RAS-like alterations; mode diagnosis was AUS in 4 of 5 BRAF V600E FNAs. CONCLUSIONS: Atypia of undetermined significance of thyroid FNAs harboring BRAF V600E is uncommon yet relatively reproducible, particularly among pathologists with experience. It is advisable to sequence BRAF across V600 in such cases.

来源:Am J Clin Pathol,查看原文。版权归原作者所有。

引用

  1. Gokozan HN, Mostyka M, Scognamiglio T, et al. Diagnostic interobserver agreement for thyroid fine-needle aspirates: Effects of reviewer experience and molecular diagnostics. Am J Clin Pathol. 2024. PMID: 38656386. doi:10.1093/ajcp/aqae043

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。